NCT02505789 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Alfieri C, Tanner J, Carpentier L, Perpête C, Savoie A, Paradis K, Delage G, Joncas J
Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood. 1996 Jan 15;87(2):812-7.
Trottier H, Buteau C, Robitaille N, Duval M, Tucci M, Lacroix J, Alfieri C
Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children. Transfusion. 2012 Dec;52(12):2653-63. doi: 10.1111/j.1537-2995.2012.03611.x. Epub 2012 Mar 15.

Transfusion-related Epstein-Barr Virus (EBV) Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients: a Multicenter Prospective Cohort Study (TREASuRE Study)

Details for clinical trial NCT02505789

Clinical trial NCT02505789 - References